ARQT (Arcutis Biotherapeutics) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARQT Arcutis Biotherapeutics Inc ARQT
56 GF Score
Price $25.08
GF Value $30.59
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Arcutis Biotherapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Arcutis Biotherapeutics is: No Data: Cannot be evaluated.

Arcutis Biotherapeutics  (NAS:ARQT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Arcutis Biotherapeutics Risk Assessment Related Terms

ARQT vs IDYA, NAMS, ALMS: Risk Assessment Comparison

For the Biotechnology subindustry, Arcutis Biotherapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcutis Biotherapeutics Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Arcutis Biotherapeutics's Risk Assessment falls into.


ARQT
56GF Score
Arcutis Biotherapeutics Inc ARQT
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arcutis Biotherapeutics (ARQT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcutis Biotherapeutics stock appears to be undervalued. The current stock price of $25.08 is trading 18% below its estimated GF Value™ of $30.59. GuruFocus considers Arcutis Biotherapeutics to be Modestly Undervalued.

Key valuation signals for ARQT:

  • Risk Assessment:
  • GF Value™: $30.59 vs. price of $25.08 (18% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the ARQT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcutis Biotherapeutics Business Description

Address 3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
56GF Score

Get the complete analysis for ARQT

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.08
Price
$30.59
GF Value